RGN-259 - RegeneRx
RegeneRx’s highest priority is the development of RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye disease and neurotrophic keratitis …
Pipeline / Clinical Trials | RegeneRx
RegeneRx drug candidate, RGN-259, is the subject of five Phase 3 clinical trials in the U.S., and EU for patients with dry eye disease (DED) and neurotrophic keratitis (NK, an orphan indication).
RGN-259 (thymosin β4) improves clinically important dry eye
Jul 12, 2018 · In this study, we investigated the effects of RGN-259 topical treatment on the cornea, conjunctiva, and lacrimal glands in a murine dry eye model, and we also compared the …
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis ...
Apr 13, 2023 · RGN-259, whose active ingredient is thymosin beta 4 (Tβ4), is a novel drug candidate that promotes cell migration, anti-inflammation, and wound healing. RGN-259 is …
Publication of RGN-259 Phase 3 Clinical Trial Results in
Jan 3, 2023 · RGN-259 is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and …
Safety and Efficacy of 0.05% and 0.1% RGN-259 for Subjects with …
RGN-259, or thymosin beta 4, is a ubiquitous low molecular weight protein that promotes cell migration and wound healing and has anti-inflammatory properties. This phase 2b/3 clinical …
ReGenTree - Pipeline
RGN-259 - Most Advanced, Preservative-Free, Single Unit Dose RGN-259 ophthalmic solution is formulated as thymosin beta 4 preservative-free eye drops for the treatment of both dry eye …
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes
Dec 29, 2022 · We determined the efficacy and safety of 0.1% RGN-259 ophthalmic solution (containing the regenerative protein thymosin ß4) in promoting the healing of persistent …
Thymosin β4 significantly improves signs and symptoms of ... - PubMed
In this small trial, RGN-259 eye drops were safe and well tolerated and met key efficacy objectives with statistically significant symptom and sign improvements, compared with vehicle …
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients …
Jan 3, 2023 · RGN-259 is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and …